Search Within

Carol Portlock

Formats
  1. Journal Article (104)
  2. Meeting Abstract (90)
  3. Book Section (10)
  4. Conference Paper (1)
  5. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (206)
  2. Department of Medicine (206)
  3. Hematologic Malignancies, Division of (206)
  4. Lymphoma (206)
  5. Survivorship Research (97)
  6. Population Sciences Research Program (66)

More Groups

People
  1. Andrew Zelenetz (116)
  2. Craig Moskowitz (106)
  3. David Straus (102)
  4. Ariela Noy (93)
  5. Paul Hamlin (82)
  6. Steven Horwitz (62)

More People

Years
  1. 2024 (3)
  2. 2021 (3)
  3. 2020 (1)
  4. 2019 (6)
  5. 2018 (2)
  6. 2017 (12)

More Years

Publications
  1. Blood (65)
  2. Journal of Clinical Oncology (22)
  3. Annals of Oncology (16)
  4. Cancer (8)
  5. British Journal of Haematology (7)
  6. Leukemia and Lymphoma (7)

More Publications

Publishers
  1. American Society of Hematology (68)
  2. American Society of Clinical Oncology (22)
  3. Oxford University Press (16)
  4. Wiley Blackwell (14)
  5. Elsevier Inc. (12)
  6. Lippincott Williams & Wilkins (11)

More Publishers

Results (206)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Hamlin, P. A.; Gabrilove, J.; Bertino, J. R.; Portlock, C. S.; Straus, D. J.; Gencarelli, A. N.; Nimer, S. D.; Zelenetz, A. D.
    Annals of Oncology (2007)

    Fulltext@MSK | Save
  • Infectious disease associations in advanced stage, indolent lymphoma (Follicular, FL and non-follicular, nFL): Developing a lymphoma prevention strategy
    Meeting Abstract

    Portlock, C. S.; Hamlin, P. A.; Noy, A.; Palomba, M. L.; Rosenzweig, L.; Walker, D.; Corcoran, S.; Chey, W. D.; Gaydos, C. A.; Schwartz, I.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Early phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies
    Meeting Abstract

    O'connor, O.; Hamlin, P.; Neylon, E.; Moskowitz, C.; Portlock, C.; Noy, A.; Sirotnak, F.; Zelenetz, A.; Mould, D.; Horwitz, S.
    EJC Supplements (2006)

    Fulltext@MSK | Save
  • Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL
    Meeting Abstract

    Moskowitz, C.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Lessac-Chenen, S.; Weaver, A.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Relapsed and refractory primary mediastinal diffuse large B-cell lymphoma: Outcome with ICE-based treatment
    Meeting Abstract

    Hamlin, P. A.; Dickson, M.; Kewalramani, T.; Horwitz, S. M.; Portlock, C. S.; Yahalom, J.; Zelenetz, A. D.; Moskowitz, C. H.
    Blood (2006)

    Fulltext@MSK | Save
  • The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Nodular lymphocyte predominant Hodgkin's disease
    Journal Article

    Portlock, C. S.
    Cancer Treatment and Research (2006)

    Fulltext@MSK | Save
  • Pegylated interferon plus rituximab in advanced stage, indolent lymphoma: Is there CD20 antigen upregulation?
    Journal Article

    Portlock, C. S.; O'Connor, O. A.; Straus, D. J.; Rosenzweig, L.; Dumitrescu, O.; Lin, O.; Maslak, P.
    Leukemia and Lymphoma (2006)

    Fulltext@MSK | Save
  • Anti-angiogenesis and diffuse large B-cell lymphoma: A new treatment opportunity?
    Journal Article

    Portlock, C.
    Leukemia and Lymphoma (2006)

    Fulltext@MSK | Save